<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114283</article-id><article-id pub-id-type="publisher-id">ACM-42003</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_96535369.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  慢性心力衰竭患者CA125水平与心功能及心室重构的相关性
  Correlation of Serum CA125 Levels with Cardiac Function and Ventricular Remodeling in Patients with Chronic Heart Failure
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孟</surname><given-names>若晨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>管</surname><given-names>军</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属青岛市立医院心内科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属青岛市立医院保健心内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1333</fpage><lpage>1338</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探究慢性心力衰竭患者血清CA125水平与心功能及心室重构的相关性。方法：入选2019年6月至2019年12月心力衰竭住院患者80例，按纽约心功能分级标准分为心功能I级15例，II级23例，III级24例，IV级18例。同时收集同期入院的体检人员60例作为对照组。采用电化学发光法测定血清CA125水平，测量左室舒张末期内径(left ventricular end-diastolic diameter, LVEDD)、左室后壁厚度(left ventricular posterior wall thickness, LVPWT)及室间隔厚度(ventricular septal thickness, IVST)、左心室质量(left ventricular mass, LVM)、左心室质量指数(left ventricular mass index, LVMI)等心功能相关指标。分析血清CA125水平与心功能及心室重构的相关性。结果：心力衰竭患者CA125水平明显高于对照组，其水平与心功能的严重程度成正比，LVEDD、LVPWT 、IVST等指标也随着心功能的加重而增加。CA125与这些指标具有正相关性(r = 0.23, 0.268, 0.284, 0.365, 0.450; P &lt; 0.05)。结论：心衰患者CA125水平越高心功能越低，其水平与心脏左心室重构呈正相关，可作为评价CHF患者心功能的一个重要指标。
   Objective: To investigate the correlation between serum CA125 level and cardiac function and ventricular remodeling in patients with chronic heart failure. Methods: In June 2019 to December 2019, 80 cases of hospitalized patients with heart failure, heart function according to the New York heart function classification standard are divided into Class I 15 cases, II 23 cases, III level 24 cases, IV 18 cases. At the same time, 60 cases of physical examination personnel hospitalized during the same period were collected as the control group. The serum CA125 level was determined by electrochemiluminescence method, and the cardiac function related indexes such as left ventricular end-diastolic diameter (LVEDD), left ventricular posterior wall thickness (LVPWT) and interventricular septal thickness (IVST), left ventricular mass (LVM) and left ventricular mass index (LVMI) were measured. The correlation between serum CA125 level and cardiac function and ventricular remodeling was analyzed. Results: The level of CA125 in patients with heart failure was significantly higher than that in the control group. The level of CA125 was directly proportional to the severity of heart function. The indexes of LVEDD, LVPWT and IVST also increased with the aggravation of heart function. CA125 was positively correlated with these indexes (r = 0.23, 0.268, 0.284, 0.365, 0.450; P &lt; 0.05). Conclusion: The higher CA125 level in patients with heart failure, the lower cardiac function. CA125 level is positively correlated with left ventricular remodeling, which can be used as an important index to evaluate cardiac function in patients with CHF.
 
</p></abstract><kwd-group><kwd>心力衰竭，CA125，心功能，心室重塑, Heart Failure</kwd><kwd> CA125</kwd><kwd> Cardiac Function</kwd><kwd> Ventricular Remodeling</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探究慢性心力衰竭患者血清CA125水平与心功能及心室重构的相关性。方法：入选2019年6月至2019年12月心力衰竭住院患者80例，按纽约心功能分级标准分为心功能I级15例，II级23例，III级24例，IV级18例。同时收集同期入院的体检人员60例作为对照组。采用电化学发光法测定血清CA125水平，测量左室舒张末期内径(left ventricular end-diastolic diameter, LVEDD)、左室后壁厚度(left ventricular posterior wall thickness, LVPWT)及室间隔厚度(ventricular septal thickness, IVST)、左心室质量(left ventricular mass, LVM)、左心室质量指数(left ventricular mass index, LVMI)等心功能相关指标。分析血清CA125水平与心功能及心室重构的相关性。结果：心力衰竭患者CA125水平明显高于对照组，其水平与心功能的严重程度成正比，LVEDD、LVPWT 、IVST等指标也随着心功能的加重而增加。CA125与这些指标具有正相关性(r = 0.23, 0.268, 0.284, 0.365, 0.450; P &lt; 0.05)。结论：心衰患者CA125水平越高心功能越低，其水平与心脏左心室重构呈正相关，可作为评价CHF患者心功能的一个重要指标。</p></sec><sec id="s2"><title>关键词</title><p>心力衰竭，CA125，心功能，心室重塑</p></sec><sec id="s3"><title>Correlation of Serum CA125 Levels with Cardiac Function and Ventricular Remodeling in Patients with Chronic Heart Failure</title><p>Ruochen Meng<sup>1</sup>, Jun Guan<sup>2</sup><sup>*</sup></p><p><sup>1</sup>Department of Healthcare Cardiology, Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Cardiology, The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/76-1572124x5_hanspub.png" /></p><p>Received: Mar. 25<sup>th</sup>, 2021; accepted: Apr. 21<sup>st</sup>, 2021; published: Apr. 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/76-1572124x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the correlation between serum CA125 level and cardiac function and ventricular remodeling in patients with chronic heart failure. Methods: In June 2019 to December 2019, 80 cases of hospitalized patients with heart failure, heart function according to the New York heart function classification standard are divided into Class I 15 cases, II 23 cases, III level 24 cases, IV 18 cases. At the same time, 60 cases of physical examination personnel hospitalized during the same period were collected as the control group. The serum CA125 level was determined by electrochemiluminescence method, and the cardiac function related indexes such as left ventricular end-diastolic diameter (LVEDD), left ventricular posterior wall thickness (LVPWT) and interventricular septal thickness (IVST), left ventricular mass (LVM) and left ventricular mass index (LVMI) were measured. The correlation between serum CA125 level and cardiac function and ventricular remodeling was analyzed. Results: The level of CA125 in patients with heart failure was significantly higher than that in the control group. The level of CA125 was directly proportional to the severity of heart function. The indexes of LVEDD, LVPWT and IVST also increased with the aggravation of heart function. CA125 was positively correlated with these indexes (r = 0.23, 0.268, 0.284, 0.365, 0.450; P &lt; 0.05). Conclusion: The higher CA125 level in patients with heart failure, the lower cardiac function. CA125 level is positively correlated with left ventricular remodeling, which can be used as an important index to evaluate cardiac function in patients with CHF.</p><p>Keywords:Heart Failure, CA125, Cardiac Function, Ventricular Remodeling</p><disp-formula id="hanspub.42003-formula76"><graphic xlink:href="//html.hanspub.org/file/76-1572124x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/76-1572124x8_hanspub.png" /> <img src="//html.hanspub.org/file/76-1572124x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>心力衰竭(Heart failure, HF)被认为是与神经激素和细胞因子激活相关的复杂综合征。同时也是多种心血管疾病的终末阶段，已经成为主要的公共卫生负担。据预测，从2012年到2030年，心力衰竭的患病率将增加46%，导致800多万成年人成为该疾病的负担 [<xref ref-type="bibr" rid="hanspub.42003-ref1">1</xref>]。有证据表明，碳水化合物抗原125 (CA 125)是一种广泛用于卵巢癌治疗监测的肿瘤标志物，在心力衰竭患者中明显升高 [<xref ref-type="bibr" rid="hanspub.42003-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.42003-ref3">3</xref>]。心室重构是心力衰竭的基本病理机制。确定心室重构的早期预测敏感指标对于预防心力衰竭很重要。本研究旨在探讨血清CA125在预测心力衰竭患者心功能及心室重构中的价值。</p></sec><sec id="s6"><title>2. 对象与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>研究对象：选取青岛市市立医院心血管内科2019年6月至2019年12月住院治疗的心力衰竭患者共80例，入选标准参考《中国心力衰竭诊断与治疗指南2018》的诊断标准 [<xref ref-type="bibr" rid="hanspub.42003-ref4">4</xref>]，其中男性47例，女性33例，年龄51~97岁，平均(74.43 &#177; 12.27)岁。I级15例，II级23例，III级24例，IV级18例。对照组：60例，男26例，女34例，平均年龄(70.83 &#177; 7.95)岁，为同期在我院保健科就诊的心功能正常患者，经心脏超声证实LVEF大于50%。排除标准：有急性心肌梗死、感染、严重的肝肾功能不全、自身免疫疾病、恶性肿瘤、脓毒症、创伤、HIV病毒感染以及纤维增生性疾病者。两组患者性别、年龄等一般资料比较均无统计学意义(P &gt; 0.05)，具有可比性。研究经医学伦理委员会批准，所有患者及家属均知情同意并签署知情同意书。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><sec id="s6_2_1"><title>2.2.1. 标本采集、检测</title><p>收集入选者年龄、性别、身高、体重指数等基本资料。入院后第2天清晨，空腹12 h，未下床活动时取肘静脉血1管约2 ml，送医院实验室行空腹血糖、甘油三酯、总胆固醇、糖化血红蛋白等的测量。通过电化学发光法测定血清CA125水平，参考值为 &lt; 35 U/mL。上述操作步骤均严格按照试剂盒说明进行。</p></sec><sec id="s6_2_2"><title>2.2.2. 超声心动图检查</title><p>超声心动图由青岛市市立医院彩超室完成。测量心功能相关指标：测定左室舒张末期内径(LVEDD)、左室后壁厚度(LVPWT)及室间隔厚度(IVST)；左心室质量(LVM)按照Devereux公式进行计算，LVM = {0.8 &#215; 1.04[3(LVPWT + IVST + LVEDD) − 3(LVEDD)] + 0.6} g，体表面积(BSA) = 0.013 &#215; 体重 + 0.06 &#215; 身高 − 0.153，左心室质量指数(LVMI) = LVM/BSA (g/m<sup>2</sup>) [<xref ref-type="bibr" rid="hanspub.42003-ref5">5</xref>]。</p></sec></sec><sec id="s6_3"><title>2.3. 统计学分析</title><p>应用SPSS 25.0软件，计量资料比较采用方差分析，计数资料采用χ<sup>2</sup>检验，等级资料采用秩和检验，采用Pearson线性相关分析评价CA125与各指标的关系。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 各组一般资料比较</title><p>HF组与对照组年龄、性别、体重指数、舒张压、胆固醇、低密度脂蛋白等指标及病史比较差异无统计学意义(P &gt; 0.05) (表1)。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general data between the two group</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >实验组</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >男[例(%)]</td><td align="center" valign="middle" >47 (57.32)</td><td align="center" valign="middle" >26 (43.33)</td><td align="center" valign="middle" >0.090</td></tr><tr><td align="center" valign="middle" >吸烟史[例(%)]</td><td align="center" valign="middle" >40 (50.00)</td><td align="center" valign="middle" >27 (45.00)</td><td align="center" valign="middle" >0.897</td></tr><tr><td align="center" valign="middle" >冠心病[例(%)]</td><td align="center" valign="middle" >55 (68.75)</td><td align="center" valign="middle" >35 (58.33)</td><td align="center" valign="middle" >0.205</td></tr><tr><td align="center" valign="middle" >高血压[例(%)]</td><td align="center" valign="middle" >50 (62.50)</td><td align="center" valign="middle" >33 (55.00)</td><td align="center" valign="middle" >0.459</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >糖尿病[例(%)]</th><th align="center" valign="middle" >35 (43.75)</th><th align="center" valign="middle" >30 (50.00)</th><th align="center" valign="middle" >0.194</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >74.43 &#177; 12.27</td><td align="center" valign="middle" >70.83 &#177; 7.95</td><td align="center" valign="middle" >0.057</td></tr><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" >125.18 &#177; 19.70</td><td align="center" valign="middle" >130.32 &#177; 14.37</td><td align="center" valign="middle" >0.065</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg)</td><td align="center" valign="middle" >73.35 &#177; 12.66</td><td align="center" valign="middle" >73.05 &#177; 10.20</td><td align="center" valign="middle" >0.938</td></tr><tr><td align="center" valign="middle" >体重指数(Kg&#183;m<sup>−1</sup>)</td><td align="center" valign="middle" >23.46 &#177; 2.87</td><td align="center" valign="middle" >24.32 &#177; 2.72</td><td align="center" valign="middle" >0.230</td></tr><tr><td align="center" valign="middle" >空腹血糖(mmol&#183;L<sup>−1</sup>)</td><td align="center" valign="middle" >6.42 &#177; 2.38</td><td align="center" valign="middle" >5.79 &#177; 1.11</td><td align="center" valign="middle" >0.062</td></tr><tr><td align="center" valign="middle" >甘油三酯(mmol&#183;L<sup>−1</sup>)</td><td align="center" valign="middle" >1.25 &#177; 0.92</td><td align="center" valign="middle" >1.49 &#177; 0.70</td><td align="center" valign="middle" >0.071</td></tr><tr><td align="center" valign="middle" >胆固醇(mmol&#183;L<sup>−1</sup>)</td><td align="center" valign="middle" >3.78 &#177; 0.97</td><td align="center" valign="middle" >4.06 &#177; 1.19</td><td align="center" valign="middle" >0.147</td></tr><tr><td align="center" valign="middle" >低密度脂蛋白(mmol&#183;L<sup>−1</sup>)</td><td align="center" valign="middle" >2.20 &#177; 0.70</td><td align="center" valign="middle" >2.36 &#177; 0.57</td><td align="center" valign="middle" >0.171</td></tr><tr><td align="center" valign="middle" >高密度脂蛋白(mmol&#183;L<sup>−1</sup>)</td><td align="center" valign="middle" >1.12 &#177; 0.65</td><td align="center" valign="middle" >1.37 &#177; 1.13</td><td align="center" valign="middle" >0.350</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 两组一般资料比较</p><p>注：1 mmHg = 0.133 kpa。</p></sec><sec id="s7_2"><title>3.2. 不同心功能分级研究对象CA125水平比较</title><p>对照组CA125水平为(9.77 &#177; 4.00) U/ml，心功能I级(15.65 &#177; 7.67) U/ml，心功能II级组(19.95 &#177; 9.84) U/ml，心功能III级组(68.80 &#177; 34.62) U/ml，心功能IV级组(149.29 &#177; 84.90) U/ml。秩和检验显示，随着患者心功能受损程度的增加，患者CA125逐渐升高(P = 0.02)，见表2。</p></sec><sec id="s7_3"><title>3.3. 各组心功能相关指标比较</title><p>LVEDD、IVST、LVPWT、LVM与LVMI水平随着患者心功能受损程度的增加逐渐升高(P &lt; 0.05)；两两比较显示，对照组LVEDD、IVST、LVPMT、LVM与LVMI水平均低于心功能I级、II级、III级、IV级组；心功能I级患者LVEDd、IVST、LVPMT、LVM与LVMI水平均低于心功能II级、III级、IV级组患者；心功能II级患者LVEDd、IVST、LVPMT、LVM与LVMI水平均低于心功能III级、IV级组患者，差异均有统计学意义(P &lt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of clinical test indexes in different group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >心功能I组</th><th align="center" valign="middle" >心功能II组</th><th align="center" valign="middle" >心功能III组</th><th align="center" valign="middle" >心功能IV组</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >例数</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >LVEDD (mm)</td><td align="center" valign="middle" >36.42 &#177; 2.34</td><td align="center" valign="middle" >42.31 &#177; 7.54<sup>1)</sup></td><td align="center" valign="middle" >45.21 &#177; 7.54<sup>1)2)</sup></td><td align="center" valign="middle" >53.24 &#177; 12.32<sup>1)2)3)</sup></td><td align="center" valign="middle" >57.90 &#177; 12.32<sup>1)2)3)</sup></td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle" >IVST (mm)</td><td align="center" valign="middle" >9.23 &#177; 1.21</td><td align="center" valign="middle" >10.24 &#177; 1.45<sup>1)</sup></td><td align="center" valign="middle" >11.23 &#177; 2.23<sup>1)2)</sup></td><td align="center" valign="middle" >11.53 &#177; 2.131<sup>)2)3)</sup></td><td align="center" valign="middle" >11.87 &#177; 3.00<sup>1)2)3)</sup></td><td align="center" valign="middle" >0.019</td></tr><tr><td align="center" valign="middle" >LVPWT (mm)</td><td align="center" valign="middle" >9.31 &#177; 1.21</td><td align="center" valign="middle" >9.89 &#177; 1.45<sup>1)</sup></td><td align="center" valign="middle" >10.02 &#177; 1.63<sup>1)2)</sup></td><td align="center" valign="middle" >11.53 &#177; 2.34<sup>1)2)3)</sup></td><td align="center" valign="middle" >11.84 &#177; 2.43<sup>1)2)3)</sup></td><td align="center" valign="middle" >0.034</td></tr><tr><td align="center" valign="middle" >LVM (mm)</td><td align="center" valign="middle" >141.45 &#177; 33.23</td><td align="center" valign="middle" >151.43 &#177; 35.56<sup>1)</sup></td><td align="center" valign="middle" >187.34 &#177; 43.54<sup>1)2)</sup></td><td align="center" valign="middle" >245.23 &#177; 46.75<sup>1)2)3)</sup></td><td align="center" valign="middle" >254.23 &#177; 87.64<sup>1)2)3)</sup></td><td align="center" valign="middle" >0.023</td></tr><tr><td align="center" valign="middle" >LVMI (g/m<sup>2</sup>)</td><td align="center" valign="middle" >84.21 &#177; 10.43</td><td align="center" valign="middle" >102.43 &#177; 11.32<sup>1)</sup></td><td align="center" valign="middle" >124.43 &#177; 11.45<sup>1)2)</sup></td><td align="center" valign="middle" >135.76 &#177; 23.98<sup>1)2)3)</sup></td><td align="center" valign="middle" >153.83 &#177; 50.21<sup>1)2)3)</sup></td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >CA125 (U/ml)</td><td align="center" valign="middle" >9.77 &#177; 4.00</td><td align="center" valign="middle" >15.65 &#177; 7.67<sup>1)</sup></td><td align="center" valign="middle" >19.95 &#177; 9.84<sup>1)2)</sup></td><td align="center" valign="middle" >68.80 &#177; 34.62<sup>1)2)3) </sup></td><td align="center" valign="middle" >149.29 &#177; 84.90<sup>1)2)3)</sup></td><td align="center" valign="middle" >0.002</td></tr></tbody></table></table-wrap><p>表2. 临床检测指标在不同分组中的比较</p><p>注：与对照组相比较：1) P &lt; 0.05；与心功能I级组比较：2) P &lt; 0.05；与心功能II级组比较：2) P &lt; 0.05；与心功能III级组比较：3) P &lt; 0.05。</p><p>注：LVEDD：左室舒张末期内径；LVPWT：左室后壁厚度；IVST：室间隔厚度；LVM：左心室质量；LVMI：左心室质量指数。</p></sec><sec id="s7_4"><title>3.4. 实验组患者机体CA125及心功能相关指标的相关性分析</title><p>心衰患者血清LVEDD、IVST、LVPWT、LVM与LVMI均呈正相关(r = 0.23, 0.268, 0.284, 0.365, 0.450; P &lt; 0.05)见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Pearson correlation analysis between serum CA125 and various indexe</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >CA125</th><th align="center" valign="middle" >r值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >LVEDD (mm)</td><td align="center" valign="middle" >0.234</td><td align="center" valign="middle" >0.027</td></tr><tr><td align="center" valign="middle" >IVST (mm)</td><td align="center" valign="middle" >0.268</td><td align="center" valign="middle" >0.035</td></tr><tr><td align="center" valign="middle" >LVPWT (mm)</td><td align="center" valign="middle" >0.284</td><td align="center" valign="middle" >0.044</td></tr><tr><td align="center" valign="middle" >LVM (mm)</td><td align="center" valign="middle" >0.365</td><td align="center" valign="middle" >0.022</td></tr><tr><td align="center" valign="middle" >LVMI (g/m<sup>2</sup>)</td><td align="center" valign="middle" >0.450</td><td align="center" valign="middle" >0.039</td></tr></tbody></table></table-wrap><p>表3. 血清CA125与各指标之间Pearson相关分析</p><p>注：LVEDD：左室舒张末期内径；LVPWT：左室后壁厚度；IVST：室间隔厚度；LVM：左心室质量；LVMI：左心室质量指数。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>心力衰竭是各种心脏结构和/或功能性疾病导致的心室收缩和/或舒张功能发生障碍，从而引起的一组临床综合征。随着我国人口老龄化的加剧，心力衰竭的患病率呈逐年上升趋势，且该病死亡率高，预后差，因此早期诊断及治疗尤为重要。慢性心力衰竭主要病理特征是心室重塑，传统的生物标志物如Ｂ型利钠肽(BNP)及N-末端脑钠肽前体(NT-proBNP)己被广泛用于心力衰竭的诊断及预后评估，但心室重塑是多种体液因子共同参与的复杂过程，因此我们需要寻找新型生物标志物来探究心室重塑的机制，从而为心力衰竭的诊治提供帮助。</p><p>CA125是一种高分子量的糖蛋白，由浆膜上皮细胞产生，在卵巢癌中升高，用于卵巢癌的诊断和随访 [<xref ref-type="bibr" rid="hanspub.42003-ref6">6</xref>]。CA-125在心外膜中表达，所以各种心脏病中CA125水平明显增高。最近有大量研究显示，CA125与心力衰竭关系密切。Nagele及其同事首先报道了在心脏移植前后慢性心力衰竭患者中几种肿瘤标志物在临床或血液动力学方面的相关性，特别是针对CA-125的发现 [<xref ref-type="bibr" rid="hanspub.42003-ref6">6</xref>]。</p><p>一项纳入了76例住院的心力衰竭患者研究发现，失代偿期心衰患者CA125水平较代偿期升高，特别是在胸腔积液和/或心包积液患者中。CA125与BNP水平显著相关，心房颤动患者CA125水平较高。据此推测出CA125可作为全身充血和容量超负荷的标志 [<xref ref-type="bibr" rid="hanspub.42003-ref7">7</xref>]。王莹莹等 [<xref ref-type="bibr" rid="hanspub.42003-ref8">8</xref>] 通过研究发现心力衰竭患者血清CA125较健康对照组增高，而LVEF值降低，血清CA125随着LVEF的降低而升高，并且随心功能分级的增加而加重，提示CA125可能与慢性心衰的发病有关。CA125除了能够评估病情，还可以推测患者预后，付祥真 [<xref ref-type="bibr" rid="hanspub.42003-ref9">9</xref>] 通过纳入12篇文献进行相关Meta分析后发现，血清CA125水平升高与HF患者全因死亡率增加密切相关，由此推测出CA125可以对HF患者的死亡风险进行预测。</p><p>本研究显示，随着患者心功能受损程度的增加患者CA125逐渐升高，说明机体CA125水平能够反映患者心功能受损程度，其水平越高患者的心功能受损越严重，其原因可能是患者心功能受损越严重，机体代偿性促进CA125水平增加，同时也反映了心衰患者液体潴留及炎症反应情况。血清CA125与左室重构存在正相关关系，其水平越高患者心脏左心室重塑的进展越严重。这与最新研究一致 [<xref ref-type="bibr" rid="hanspub.42003-ref10">10</xref>]，心室重构组的血清CA125水平明显高于非心室重构组和对照组。另外，血清CA125水平LVMI呈显著正相关。CA125水平不仅能够反映HF患者心功能受损程度，且与患者左心室重塑存在密切关系，CA125水平异常升高的原因如下：1、心力衰竭患者血清中原癌基因的过表达增加了CA125的分泌并促进了心肌重塑。2、炎症刺激学说，众所周知，促炎细胞因子在CHF的发病机制和预后中起着重要作用。心衰患者体内存在神经–内分泌系统激活，细胞因子的过度活化，大量炎性细胞因子的释放，刺激间皮细胞过度表达CA125。这些炎性因子的级联反应参与了心力衰竭的病理生理过程，导致心肌重构的发生。经研究证实 [<xref ref-type="bibr" rid="hanspub.42003-ref11">11</xref>] 不仅在冠状静脉窦中，而且在CHF患者的鼻窦血液中，血清CA125和NT-proBNP水平均与炎症因子有关，考虑是细胞因子激活的结果。</p><p>总之，血清CA125水平与心力衰竭患者心功能分级及心室重构密切相关，可作为心衰患者诊断及判断预后的一项指标，具体机制亟待更深入研究来揭示。</p></sec><sec id="s9"><title>文章引用</title><p>孟若晨,管 军. 慢性心力衰竭患者CA125水平与心功能及心室重构的相关性Correlation of Serum CA125 Levels with Cardiac Function and Ventricular Remodeling in Patients with Chronic Heart Failure[J]. 临床医学进展, 2021, 11(04): 1333-1338. https://doi.org/10.12677/ACM.2021.114283</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42003-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Abuzaanona, A. and Lanfear, D. (2017) Pharmacogenomics of the Natriuretic Peptide System in Heart Failure. Current Heart Failure Reports, 14, 536-542. &lt;br&gt;https://doi.org/10.1007/s11897-017-0365-5</mixed-citation></ref><ref id="hanspub.42003-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">吴华芹, 张并璇, 李雨濛, 等. 慢性心力衰竭病人血清CA125水平与心功能的相关性研究[J]. 中西医结合心脑血管病杂志, 2020, 18(18): 2955-2958.</mixed-citation></ref><ref id="hanspub.42003-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Y.X., Wang, X.Q., Fang, C.F., et al. (2008) Value of BNP and Tumour Marker CA125 in Patients with Heart Failure. Acta Cardiologica, 63, 501-506. &lt;br&gt;https://doi.org/10.2143/AC.63.4.2033050</mixed-citation></ref><ref id="hanspub.42003-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志, 2018, 46(10): 760.</mixed-citation></ref><ref id="hanspub.42003-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">徐洁, 骆小梅, 张颖. 慢性心力衰竭患者血清脂联素水平与心功能及左室重构的相关性[J]. 中国老年学杂志, 2017, 37(1): 91-93.</mixed-citation></ref><ref id="hanspub.42003-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hung, C.L., Hung, T.C., Lai, Y.H., et al. (2013) Beyond Malignancy: The Role of Carbohydrate Antigen 125 in Heart Failure. Biomarker Research, 1, 25. &lt;br&gt;https://doi.org/10.1186/2050-7771-1-25</mixed-citation></ref><ref id="hanspub.42003-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ueland, T., Gullestad, L., Nymo, S.H., et al. (2015) Inflammatory Cytokines as Biomarkers in Heart Failure. Clinica Chimica Acta, 443, 71-77. &lt;br&gt;https://doi.org/10.1016/j.cca.2014.09.001</mixed-citation></ref><ref id="hanspub.42003-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">王莹莹, 陶绍能, 戴云海, 等. 血清CA125在慢性心力衰竭患者中的临床价值[J]. 皖南医学院学报, 2019, 38(4): 354-356.</mixed-citation></ref><ref id="hanspub.42003-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">付祥真, 罗霖, 丁雪峰, 等. 糖类抗原125对心力衰竭患者预后预测价值的Meta分析[J]. 临床心血管病杂志, 2020, 36(12): 1098-1103.</mixed-citation></ref><ref id="hanspub.42003-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Xie, Y.T., Dang, Y., Zhang, F.F., et al. (2020) Combination of Serum TIMP-3, CA125, and NT-proBNP in Predicting Ventricular Remodeling in Patients with Heart Failure Following Acute Myocardial Infarction. Cardiovascular Diagnosis and Therapy, 10, 1184-1191. &lt;br&gt;https://doi.org/10.21037/cdt-20-399</mixed-citation></ref><ref id="hanspub.42003-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Stanciu, A.E., Stanciu, M.M. and Vatasescu, R.G. (2018) NT-proBNP and CA 125 Levels Are Associated with Increased Pro-Inflammatory Cytokines in Coronary Sinus Serum of Patients with Chronic Heart Failure. Cytokine, 111, 13-19. &lt;br&gt;https://doi.org/10.1016/j.cyto.2018.07.037</mixed-citation></ref></ref-list></back></article>